Physiomics plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK
Tel 01865 784980
Fax 08701 671931
5 January 2009
Physiomics plc ('Physiomics' or 'the Company')
Holding in Company
The Company has been informed that following a sale of 19,000,000 Ordinary Shares of 0.04p each ('Ordinary Shares') on 16 December 2008 by Billam AG, Billam AG now holds 40,500,000 Ordinary Shares in the Company, representing 6.48% of the Company's total voting rights.
For further information:
Physiomics plc +44 (0)1865 784980
Dr Christophe Chassagnole, COO
E-mail: cchassagnole@physiomics-plc.com
Grant Thornton UK LLP +44 (0)20 7383 5100
Philip Secrett, Colin Aaronson
About Physiomics plc
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of 'virtual cells'.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002